Is it safe for patients with renal failure to receive gadolinium intravenously for contrast-enhanced MRI examinations?
With more data coming in regarding the incidence of Nephrogenic Systemic Fibrosis (NSF) in patients with renal insufficiency receiving gadolinium-based contrast agent, the FDA recently issued an update to their public health advisory, advising caution with patients with moderate to end-stage renal disease.